About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Way to Treat Ischemic Pathologies Uncovered by Researchers from CIC BioGUNE

by Rajashri on August 6, 2009 at 8:49 PM
Font : A-A+

 Way to Treat Ischemic Pathologies Uncovered by Researchers from CIC BioGUNE

A new area of research which looks extremely promising as regards the development of new therapeutic responses to ischemic pathologies and cardiovascular diseases in general has been developed by a team of researchers from CIC bioGUNE from the Cellular Biology and Stem Cell Unit, alongside a team from Paris' Cardiovascular Research Centre (INSERM U970.

The results of this research project, which was initiated in 2005 and is supported by Bizkaia:Xede and the Basque Government's Etortek programme, were published in the prestigious scientific journal Circulation.

Advertisement

By activating a protein called HIF, the strategy is to stimulate revascularisation and the repair of the damaged organ following ischemia caused by the obstruction of a blood vessel preventing normal blood flow. These obstructions occur, for example, in the event of thrombosis in a limb, myocardial infarction or a stroke. In this sense, it is important to highlight the fact that cardiovascular diseases are the principal cause of death throughout the world (in the European Union, they account for 40% of all deaths, a figure equivalent to 2 million deaths per year).

In general, cells tend to respond to the lack of oxygen caused by poor blood flow by activating HIF. However, in the case of an ischemic pathology, HIF is not sufficiently activated.
Advertisement

Dr Berra, Cellular Biology and Stem Cell Unit's leader, stated that they decided to over-produce HIF following ischemia as an attractive therapeutic alternative. For their research purposes, they used an ischemic model provoked in a mouse leg through ligation of the femoral artery. In other words, they closed off the femoral artery and stopped the blood flow to the limb. When this happens, the leg develops necrosis and after a time, the mouse dies.

The aim was to artificially help stimulate the production of HIF after the femoral artery had been closed off. And they saw that when they did this, the mouse's leg revascularised and no longer entered into a degenerative process.

How is this high level of HIF production achieved? HIF is a protein which, when not required, degrades constitutively and this degradation is regulated by enzymes called PHDs.

These enzymes hydroxylate HIF and, as a result of this hydroxylation, the protein degrades. Therefore, when these enzymes are inhibited, HIF cannot degrade and so accumulates. To inhibit PHDs, they use siRNAs, explains Dr Berra.



Source: Eurekalert
RAS
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Indian Medical Journals Drug Side Effects Calculator Hearing Loss Calculator Find a Doctor Loram (2 mg) (Lorazepam) Sanatogen Accident and Trauma Care Iron Intake Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Nutam (400mg) (Piracetam)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Way to Treat Ischemic Pathologies Uncovered by Researchers from CIC BioGUNE Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests